Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not uncommon for individuals to seek out a weight management aid, such as a ...

Here are the eight FDA-approved weight loss medications: Ozempic and Wegovy. Semaglutide, the active ingredient in Ozempic and Wegovy, mimics a natural hormone called GLP-1, according to WebMD.It ...

FDA approves Eli Lilly's Zepbound drug for weight loss 01:59. The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Wegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.

The Food and Drug Administration (FDA) on Friday approved a weight loss drug for overweight or obese adults, marking the first such authorization since 2014.

The FDA approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind. Accessibility statement Skip to main content.

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

In February, FDA advisers also recommended approval of Qnexa, another weight-loss drug. The FDA had rejected Qnexa in 2010 because of concerns about heart problems and birth defects.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

FDA approves weight loss drug Zepbound to treat obstructive sleep apnea. Updated December 22, 2024 5:10 PM ET Originally published December 21, 2024 1:06 PM ET. Juliana Kim ...